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Abstract
Background: Liver cancer, of which hepatocellular carcinoma (HCC) is by far the most common type, is the second
most deadly cancer (746,000 deaths in 2012). Currently, the only curative treatment for HCC is surgery to remove
the malignancy (resection) or to remove the entire diseased liver followed by transplantation of healthy liver tissue.
Given the shortage of healthy livers, it is crucial to provide transplants to patients that have the best chance of
long-term survival. Currently, transplantation is determined via the Milan criteria—patients within Milan (single
tumor < 5 cm or 2–3 tumors < 3 cm with no extrahepatic spread nor intrahepatic vascular invasion) are typically
eligible for transplantation. However, combining microRNA expression profiling with the Milan criteria can improve
prediction of recurrence.
HCC often presents with multiple distinct tumor foci arising from local spread of a primary tumor or from the
oncogenic predisposition of the diseased liver. Substantial genomic heterogeneity between tumor foci within a
single patient has been reported; therefore, biomarker development must account for the possibility of highly
heterogeneous genomic profiles from the same individual.
Methods: MicroRNA profiling was performed on 180 HCC tumor samples from 89 patients who underwent liver
transplantation at the University of Rochester Medical Center. The primary outcome was recurrence-free survival
time, and patients were observed for 3 years post-transplantation.
Results: MicroRNA expression profiles were used to develop a biomarker that distinguishes HCC patients at greater
risk of recurrence post-transplantation. Unsupervised clustering uncovered two distinct subgroups with vast
differences in standard transplantation selection criteria and recurrence-free survival times. These subgroups were
subsequently used to identify microRNAs strongly associated with HCC recurrence. Our results show that reduced
expression of five specific microRNAs is significantly associated with HCC recurrence post-transplantation.
Conclusions: MicroRNA profiling of distinct tumor foci, coupled with methods that address within-subject tumor
heterogeneity, has the potential to significantly improve prediction of HCC recurrence post-transplantation. The
development of a clinically applicable HCC biomarker would inform treatment options for patients and contribute
to liver transplant selection criteria for practitioners.
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Background
Hepatocellular carcinoma (HCC) is one of the most
common malignancies worldwide, accounting for the
second most cancer-related deaths [1, 2]. In the U.S., it
has been predicted by 2030 to become the third leading
cause of cancer-related death, surpassing breast, prostate,
and colorectal cancers [3]. The only curative treatment is
surgery: either tumor resection or liver transplantation.
However, patients undergoing these treatments still have a
high risk of recurrence. Both resection and transplantation
result in 80 % 5-year patient survival rates in appropriately
selected patients. However, the recurrence rate in 5 years
for resection is 70 % whereas with transplantation the
5-year recurrence rate is 15–20 % [4]. Even though the
5-year HCC recurrence rate after transplantation
seems acceptably low at 15–20 %, improved selection
criteria would further optimize outcomes and therefore
more efficiently use the precious resource of donor
liver tissue. The current selection criteria for transplant-
ation, the Milan criteria, are a single tumor < 5 cm or 2–3
tumors < 3 cm with no extrahepatic spread or intrahepatic
vascular invasion [5]. While the Milan criteria alone per-
form reasonably well, combining the Milan criteria with a
microRNA biomarker has been shown to improve predic-
tion of recurrence [6].
MicroRNAs are receiving growing attention as bio-
markers due to their diverse role in cellular regulation.
In cancer, microRNAs have shown promise as both diag-
nostic and prognostic biomarkers [7]. A recent study re-
ported a microRNA biomarker of HCC recurrence after
liver transplantation from serum exosome samples [8].
Other studies have proposed microRNA biomarkers of
HCC recurrence based on microRNA expression profiles
from solid tumor biopsies [9–12].
Tumor biopsy followed by histopathology, or more re-
cently genomic analysis, is a standard procedure to as-
sess the type, severity, and prognosis of many cancers.
Typically only one biopsy is taken from each patient.
While this may be sufficient to determine whether a
mass is malignant or benign, it is insufficient to capture
within-patient tumor heterogeneity, which has been
shown to exist both between tumor foci [13, 14] and
within a single tumor [15, 16]. Therefore, biopsying and
analyzing only one sample per patient runs the risk of
failing to capture the cells driving the malignant pheno-
type. While the goal of precision medicine is to harness
between-patient tumor heterogeneity to tailor treatment
to specific features of an individual's cancer profile,
within-patient tumor heterogeneity poses a serious chal-
lenge to this goal. Within-patient tumor heterogeneity
affects both biomarker development and application.
During development, heterogeneity will reduce the
power to detect genomic signatures associated with the
phenotype of interest. Even if a biomarker is successfully
developed, both good and poor prognosis signatures
may be present within the same patient complicating
clinical application.
Hepatocellular carcinoma (HCC) is particularly well
suited to the study of within-patient heterogeneity be-
cause it often presents with multiple tumor foci. In pa-
tients with multifocal HCC, the individual lesions can
arise from either local dissemination of the primary
tumor or from the oncogenic predisposition of the dis-
eased liver. In the latter case, a patient with multifocal
HCC may have multiple tumors that are clonally unre-
lated and presumably exhibit distinct genomic profiles.
This presents a challenge to genomic analyses attempting
to associate sample-level genomic profiles (e.g. microRNA
expression) with patient-level phenotypic data (e.g.
recurrence-free survival). Furthermore, recurrence of
HCC post-transplantation is commonly associated
with multifocal tumors.
The goals of this study are to: (1) further examine the
association between microRNA expression, current
transplantation selection criteria, and HCC recurrence,
and (2) to develop a biomarker of HCC recurrence post-
transplantation that is able to incorporate information
from multiple tumor foci. The approach proposed in this
paper addresses the challenge of within-patient heterogen-
eity by developing a sample-level model of recurrence and
coupling this model with patient-level information to
make predictions.
Methods
Patient and sample description
The data are comprised of 180 tumor samples from 89
HCC patients who underwent liver transplantation at
the University of Rochester Medical Center (GEO Series
accession number GSE67140). This study was performed
with approval of the University of Rochester Research
Subjects Review Board (RSRB00029467). Liver explant
pathology specimens (paraffin embedded blocks) from
patients undergoing liver transplant for HCC were de-
identified prior to processing and analysis, so individuals
were exempt from consent. Demographics of the patient
cohort are shown in Additional file 1: Table S1. Of these
97 tumor samples from 69 HCC patients were previ-
ously described in Barry et al. [6]. By nearly doubling the
number of tumor samples, we are able to investigate the
effect of within-subject heterogeneity on microRNA bio-
markers of HCC recurrence. Each patient was observed
for 3 years and recurrence-free survival time (or censor-
ing time) was recorded.
MicroRNA purification and array hybridization
Samples were isolated, hybridized, and processed exactly
as in Barry et al. [6]. The Roche High Pure miRNA isola-
tion kit (Roche Diagnostics, Mannheim, Germany) was
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used to isolate miRNA from formalin-fixed paraffin em-
bedded (FFPE) liver tumor tissues. Samples were assessed
for the presence of enriched miRNA using an Experion
Bioanalyzer (Bio-Rad, Hercules, CA, USA). MicroRNA
labeling was performed using the FlashTag Biotin RNA
labeling kit (Genisphere, Hatfield, PA, USA). MicroRNA
expression was assessed using Affymetrix GeneChip
miRNA 1.0 microarrays (Affymetrix, Santa Clara, CA,
USA). Array hybridization, washing, and staining was
performed at the Upstate Medical University microarray
core facility in Syracuse, NY, according to the manufac-
turer’s instructions. Arrays were scanned using a Gene-
Chip Scanner 7G Plus.
Quality control and data preprocessing
Array quality was assessed by visual inspection of re-
sidual pseudo chip images, Normalized Unscaled Stand-
ard Error (NUSE) medians and interquartile ranges, and
Relative Log Expression (RLE) medians and interquartile
ranges [17]. Of the 10 poor quality arrays, 6 were rehy-
bridized resulting in improved quality. There was insuffi-
cient genetic material to rehybridize the other four poor
quality samples. Analysis was performed on 176 samples
of acceptable quality from 89 HCC patients.
The data included in this study span four distinct
batches, based on the date on which the microarray
hybridization occurred. Samples from the same patient
sometimes span multiple batches. All samples were
processed and analyzed in the same manner.
Arrays were preprocessed using Robust Multi-array
Average (RMA) [18]. Subsequent analysis was re-
stricted to the 847 human microRNA probe sets.
Recurrence-free survival time was the primary out-
come of interest in these data. All data analyses were
performed using the R/Bioconductor statistical com-
puting environment [19]. The processed data and R
scripts needed to reproduce all analyses were submit-
ted with this manuscript as additional data files and
made freely available on GitHub: https://github.com/
mccallm/HCCmicroRNA.
MicroRNA expression in multifocal tissue samples
For patients with unifocal HCC, patient-level and
sample-level models are identical. In other words, re-
currence post-transplantation is predicted based on
the single observed sample. In the case of multifocal
HCC, we obtained multiple samples from distinct
tumor foci. In this case, it is important to distinguish
between patient-level and sample-level modeling. Sam-
ples from the same individual may have vastly different
genomic profiles. As such, it is crucial to distinguish
between the sample(s) that are driving recurrence and
those that are not.
Visualization and examination of sample-level clustering
First, we used the t-Distributed Stochastic Neighbor Em-
bedding (t-SNE) technique to visualize the distribution
of samples. The t-SNE is a nonlinear dimensionality
reduction technique that facilitates visualization of high
dimensional data in two or three dimensions [20]. It is
implemented in the R package Rtsne. Principal Compo-
nent Analysis (PCA) was also used to visualize the data
in a low dimensional space.
Second, we use several unsupervised learning algorithms
to identify potential subgroups within the data. We eval-
uated nine different unsupervised learning methods
(Hierarchical clustering, KMeans, DiANA, Fanny, Pam,
Clara, Som, Sota and Model based clustering) using the
clValid package, and found that KMeans with 2 clusters
resulted in the clearest separation between subgroups in
our data. This appears consistent with the results from
the t-SNE analysis.
Feature selection
One KMeans cluster (cluster one) consists mostly of
samples from HCC recurrent patients, and the other
cluster (cluster two) includes samples from both recur-
rent and non-recurrent patients. Samples from recurrent
patients in cluster one are labeled as poor prognosis, and
samples from non-recurrent patients in cluster two are
labeled as good prognosis. The former class is comprised
of 22 samples, and the latter contains 66 samples. These
class labels address the possible ambiguity for multifocal
patients with samples in both clusters and are used as
training data for feature selection. By selecting the train-
ing data in this manner, we guarantee that there are no
patients who have samples in both the training and test-
ing sets.
We used the 88 selected samples and their class labels
to determine features that are associated with poor prog-
nosis. Mutual information was used to measure the con-
tribution of each feature to sample classification. The
mutual information of a feature (X) and a class (Y) is
the expected value of the point-wise mutual information
over the HCC recurrence and non-recurrence outcomes,
as follows:





p x; yð Þ log p x; yð Þ
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 
;
We do not assume a linear association between micro-
RNA expression and HCC recurrence. Instead we
discretize microRNA expression into four intervals:
[Min,Q1], [Q1,Q2], [Q2,Q3], [Q3,Max] where Q1, Q2,
and Q3 represent the first, second, and third quartiles of
expression for a given feature. Mutual information was
calculated for each feature across the four intervals. The
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greater the mutual information value, the more the fea-
ture is associated with HCC recurrence.
Biomarker assessment
We applied Naïve Bayes and Support Vector Machine
learning models to assess the ability of the proposed bio-
marker to predict sample membership in the subgroups.
The Naive Bayes and Support Vector Machine functions
are from R package, e1071 version 1.6-4. The Support
Vector Machine kernel type used was a radial basis with
a cost value of 1000. For both classifiers, the 88 previ-
ously described samples were used as training data and
the remaining 88 samples as test data. While multiple
samples may come from the same patient, no patient
had samples in both the training and test data sets.
Results
Visualization of microRNA Expression Reveals Two
Subgroups
The data consist of 847 microRNAs measured across
176 samples. t-Distributed Stochastic Neighbor Embed-
ding (t-SNE) facilitates visualization of high dimensional
data in a low-dimensional space [20]. Samples that clus-
ter in the low-dimensional space have a higher probabil-
ity of association in higher dimensions. Projection of the
microRNA expression data into two-dimensional space
(Fig. 1) shows that the samples form two distinct
subgroups. In the top left subgroup, most of the samples
are from recurrent patients, while samples in the bottom
right subgroup are from a mix of recurrent and non-
recurrent patients. A plot of the first two principal
components (Additional file 1: Figure S1) also shows
separation into two distinct subgroups. Because recur-
rence applies to patients not samples, unsupervised
sample-level analyses have the potential to uncover
within-patient heterogeneity.
Unsupervised Clustering into Two Subgroups
To gain more insight into the groups observed in Fig. 1,
we used KMeans clustering to group the data into two
clusters. Similar to the t-SNE grouping, cluster 1 was
comprised primarily of samples from recurrent patients,
and cluster 2 was comprised of samples from both re-
current and non-recurrent patients. For each sample, we
calculated the distance between its microRNA expres-
sion profile and the average expression profile of each
subgroup (i.e. the two KMeans cluster centers). An MA-
plot of the difference in distances (M = d2-d1) versus the
average distance (A = {d1 + d2}/2) shows a clear separ-
ation between the two subgroups (Fig. 2). Subgroup 1
(above the dashed line in Fig. 2) is comprised of 50
Fig. 1 Two-dimensional representation of microRNA expression profiles.
176 samples with 847 dimensions are mapped into two dimensions via
t-Dimensional Stochastic Neighbor Embedding using the Rtsne package.
Samples closer together have more similar microRNA expression profiles.
The samples from HCC recurrent patients are indicated with red
triangles. The samples from non-recurrent patients are indicated
with black circles. The majority of samples in the upper left are from
recurrent patients; those in the bottom right are from a mixture of
recurrent and non-recurrent patients
Fig. 2 MA-plot of distance between the microRNA expression profile
of each sample and the average expression profile of each subgroup.
Large values of M correspond to samples that are far more similar
to the average expression profile of subgroup 1 than subgroup 2.
Large values of A correspond to samples that differ from the
average expression profile of both subgroups. The dashed
horizontal line (y = 0) indicates samples that are equidistant from
both cluster centers. A square indicates a sample from a patient all
of whose samples are from cluster 1. A circle indicates a sample
from a patient all of whose samples are from cluster 2. A triangle
indicates a sample from a patient whose samples are from both
cluster 1 and cluster 2
Xie et al. BMC Medical Genomics  (2016) 9:18 Page 4 of 11
samples, 43 of which are from recurrent patients and 7
of which are from non-recurrent patients. Subgroup 2
(below the dashed line in Fig. 2) is comprised of 126
samples, 71 of which are from non-recurrent patients
and 55 of which are from recurrent patients. The data
were acquired in four batches as described in the
Methods Section. The batch in which the data were col-
lected and analyzed does not appear to be strongly asso-
ciated with subgroup, with the possible exception of
batch 3, which is comprised of primarily non-recurrent
patients (Additional file 1: Figure S2).
In Fig. 2, the labels, Recurrence and No Recurrence, are
applied to all samples from a given patient; however, not
all of the samples from that patient necessarily contrib-
uted to the recurrence. Since a patient with multifocal
disease may have multiple samples analyzed, and just
one sample might be responsible for the recurrence, the
samples in cluster 2 could include relatively benign sam-
ples from either HCC recurrent patients or non-
recurrent patients. In fact, 21 out of 55 samples (38 %)
from recurrent patients in cluster 2 come from patients
with at least one sample in cluster 1. In contrast, only 5
out of 71 samples (7 %) from non-recurrent patients in
cluster 2 come from patients with at least one sample in
cluster 1. This suggests that many of the samples from
recurrent patients that fall in cluster 2 may not be re-
sponsible for the recurrence; rather a different sample
from the same patient that falls in cluster 1 may be re-
sponsible for the recurrence. This highlights the ration-
ale for using unsupervised clustering – the relationship
between recurrence status and microRNA expression is
complicated by the heterogeneity between samples from
the same patient.
Sample-Level Clustering Is Associated with Patient
Survival
Combining sample-level information across tumor foci,
we can categorize patients into three groups. The first
group is comprised of patients all of whose samples are
in cluster 1. The second group is made up of patients all
of whose samples are in cluster 2. The third group con-
sists of patients with samples in both cluster 1 and cluster
2 (labeled as Mixed). Additional file 1: Table S2 shows the
distribution of samples between clusters stratified by the
number of samples per patient. Kaplan-Meier survival
curves for each of these three patient groups (Fig. 3) show
that recurrence-free survival time is strongly differentiated
by membership in one of the three groups (p-value =
1.3x10−5). A Cox proportional hazards model shows a sta-
tistically significant difference between the poor prognosis
and good prognosis groups but no discernable difference
between the poor prognosis group and the mixed group
(Additional file 1: Table S3). The hazard ratios from a
multivariate Cox regression (Additional file 1: Table S4)
and Kaplan-Meier curves stratified by batch (Additional
file 1: Figure S3) demonstrate that the results do not ap-
pear to be strongly dependent on the batch variable.
While there appears to be a strong association between
group membership and recurrence-free survival, it is use-
ful to look at the relationship between these groups and
current clinical criteria for transplantation.
Association of microRNA expression with clinical
covariates
Additional file 1: Figure S4 shows the association be-
tween the two microRNA-based subgroups and four
clinical criteria for transplantation: (A) vascularization,
(B) focality, and (C) number of tumors, as well as (D)
the Milan criteria (a combination of the other criteria).
In general, criteria that favor transplantation are less
common in the poor prognosis subgroup (cluster 1). Of
note, 100 % (50/50) of samples in the poor prognosis
subgroup are from vascularized tumors, while only 24 %
(30/126) of the samples in the good prognosis subgroup
show increased vascularization. Also, 84 % (42/50) of
samples in the poor prognosis subgroup are from pa-
tients who fall outside the Milan criteria. In contrast,
39 % (49/126) of samples in the good prognosis sub-
group are from patients who fall within the Milan
Fig. 3 Kaplan-Meier curves of recurrence-free survival for all 89
patients stratified by subgroup membership of individual samples.
The p-value suggests that recurrence-free survival time is strongly
differentiated by subgroup. The red curve includes 14 patients with
samples from cluster 1 only. The black dashed curve includes 58
patients with samples exclusively from cluster 2, and the blue dotted
curve includes 17 patients with samples from both cluster 1 and
cluster 2. Patients with one or more samples from cluster 1 (red and
blue curves) appear to have a similar prognosis, while patients with
samples only from cluster 2 (black curve) appear to have significantly
better prognosis
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criteria. The Milan criteria reflect primarily patient-level
measurements, so interpretation of their association with
sample-level microRNA expression profiles is complicated
by patients with samples in both subgroups. Additional
file 1: Table S5 shows the distribution of patients across
the Milan criteria and microRNA expression clusters. For
the poor prognosis group, half (7/14) of the patients are
outside Milan and half (7/14) are within Milan. For the
good prognosis group the split is 30 of 58 within Milan
and 28 of 58 outside Milan. The 17 patients in the mixed
group are all outside Milan.
Previous work reported a biomarker that was strongly
associated with recurrence-free survival time independent
of Milan status [6]. While our unsupervised sample-level
analysis showed a strong association with recurrence-free
survival (Fig. 3) and a similar association in patients out-
side Milan (Additional file 1: Figure S5A), it did not show
a significant association with recurrence-free survival time
for patients within Milan (Additional file 1: Figure S5B).
In fact, patients outside Milan with microRNA expression
profiles all in the good prognosis subgroup had similar
recurrence-free survival to patients within Milan (Fig. 4),
and both of these groups differed significantly from pa-
tients outside Milan with at least one poor prognosis
sample. A Cox proportional hazards model shows a sta-
tistically significant difference between the Within
Milan group and the Outside Milan & Cluster 1 (poor
prognosis) group as well as the Outside Milan & Mixed
group; however there was no discernable difference be-
tween the Within Milan group and the Outside Milan &
Cluster 2 (good prognosis) group (Additional file 1:
Table S6).
This latter group, Outside Milan & Cluster 2 (good
prognosis), represents a group of patients who would be
deemed unfit for liver transplantation based on the
Milan criteria but would appear to have a good chance
of recurrence free survival if they received a liver trans-
plant. In summary, it appears that there is a subset of
patients who would benefit from microRNA profiling
when used with the Milan criteria to determine trans-
plantation. However, it is unlikely that all 847 micro-
RNAs used to differentiate between the good and poor
prognosis subgroups are associated with HCC recur-
rence, nor would it be practical to perform microRNA
profiling of tumor biopsies unless absolutely necessary.
To obtain a clinically applicable microRNA biomarker, it
is desirable to identify a subset of microRNAs that are
actually associated with HCC recurrence.
Feature selection
The previous results are based on the expression of 847
microRNAs in each sample. We hypothesize that a rela-
tively small subset of these are the primary biomarkers
for HCC recurrence. To find such features, we used
mutual information as described in the Materials and
Methods Section. After calculating the mutual informa-
tion for each microRNA, we selected the top five fea-
tures, which had mutual information values much
greater than the rest (Additional file 1: Table S7). These
five features are miR-122_st, miR-126_st, miR-15a_st,
miR-22_st and miR-30a_st. Classification of patients into
poor, mixed, and good prognosis clusters based on the
expression of these five microRNAs exactly matched the
classification using all 847 microRNAs. This means that
the results shown in the Kaplan-Meier survival curves
(Fig. 4) and Cox proportional hazard model (Additional
file 1: Table S6) are identical whether one uses all 847
microRNAs or just these 5 microRNAs.
The first feature, miR-122, is specific to the liver and a
reduced level of miR-122 is associated with HCC pro-
gression and metastasis [21]. Next, miR-126 regulates
angiogenesis and is normally expressed in endothelial
cells, such as capillaries and larger blood vessels. It is
Fig. 4 Kaplan-Meier curves of recurrence-free survival as delineated
by Milan criteria and clustering on all 89 patients. The patients within
Milan are not stratified by their microRNA expression profile because
microRNA expression is not significantly associated with survival for
patients within Milan (Figure S5). Recurrence-free survival time is
strongly differentiated by subgroups defined by the Milan criteria
and microRNA expression profiles (p-value = 1.6x10−13). Of note is
that patients outside Milan whose samples all fall in cluster 2
(dashed black) have recurrence survival times that are nearly as good
as patients within Milan (p-value = 0.44). Moreover, both of these
subgroups have significantly different recurrence-free survival times
than the other two subgroups: Outside Milan & Cluster 1 (7 patients)
vs. Outside Milan & Cluster 2 (28 patients): p-value = 1.05x10−7;
Outside Milan & Cluster 1 vs. Within Milan (37 patients): p-value =
1.03x10−12; Outside Milan & Mixed (17 patients) vs. Outside Milan
& Cluster 2: p-value = 2.28x10−3; Outside Milan & Mixed vs. Within
Milan: p-value = 1.89x10−5
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also associated with innate immune response [22]. Func-
tioning as a tumor suppressor, miR-15a targets oncogene
BCL2, and within tumor cells miR-15a itself is down
regulated [23]. In several cancers, miR-22 has been
shown to be associated with differentiation, metastasis
and prognosis. In HCC, miR-22 is especially down reg-
ulated [24]. Down-regulation of miR-30a in HCC is
strongly associated with decreased disease-free sur-
vival. In addition, tumor cell migration, invasion and
epithelial-mesenchymal transition are associated with
its down-regulation [25]. In a recent study on micro-
RNA profiling in HCC vascular invasion, miR-122,
miR-126, miR-15a, and miR-30a are down regulated in
HCC samples with vascular invasion [26].
Discretized microRNA expression is associated with
recurrence-free survival
Figure 5 shows the recurrence free survival curves based
on the four different expression intervals for the top five
microRNAs. Patients with samples in the lowest interval,
[min,Q1], have significantly worse survival than those
with samples in the other three intervals. This suggests
an association between recurrence and reduced expres-






Fig. 5 The relationship between microRNA expression and recurrence free survival time was examined for the five microRNAs with the highest
mutual information: (a) miR-122_st, (b) miR-126_st, (c) miR-30a_st, (d) miR-22_st, and (e) miR-15a_st. Kaplan-Meier HCC recurrence free survival for
5 microRNAs. Each of the 4 curves in the figures indicates survival times for a different quartile of microRNA expression values, with red being the
lowest values and green the highest. It is clear from the red curves representing the lowest quartile expression values, that poor recurrence-free
survival is associated with low levels of expression of these 5 microRNAs—p-values: 8.8x10−11 (miR-122), 9.6x 10−11 (miR-126), 5X10−12 (miR-22),
2.8x10−11 (miR-30a), 8.6x10−14 (miR-15a)
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S6–S10 show the expression values for the 5 miRNAs
stratified by patient and colored by prognosis group.
The centers shown in the figures (poor prognosis center
and good prognosis center) are K-Means centers for
each group.
The expression of these 5 microRNAs can be used to
predict recurrence more expediently than using the full
set of 847 microRNAs. To confirm the reduced feature
set, we used supervised machine learning models to clas-
sify samples as poor or good prognosis. Specifically, we
used naïve Bayes and support vector machine learning
models with these five microRNA features. As described
in the Material and Methods Section, half the samples
were used for training and the other half for testing. The
naïve Bayes model successfully classifies 28 of the testing
samples as poor prognosis, and 60 as good prognosis.
The support vector machine model replicates the naïve
Bayes results. Given that the poor prognosis class was
shown to be strongly associated with recurrence, we can
conclude that these five microRNAs are an effective re-
duced feature set.
Finally, we examined the association between these
five microRNAs and the measured clinical covariates.
These 5 microRNAs appear to be associated with recur-
rence and vascularization, and to a lesser degree tumor
stage, HCV, and the Milan criteria (Additional file 1:
Figures S11–S15).
Relationship to Previously Published Biomarker Approach
A previous approach to addressing within-subject het-
erogeneity in a subset of these data was to summarize
from sample-level microRNA expression to patient-level
profiles by considering the two extrema for each micro-
RNA (the minimum and maximum observed values
within each patient) [6]. This approach was used to
identify a biomarker of HCC recurrence in a subset of
the data considered in this manuscript. Of the five
microRNAs identified in this manuscript, two were also
part of the previous biomarker, miR-122 and miR-22.
To examine the performance of the previous approach,
we applied the min/max procedure to summarize micro-
RNA expression to the patient level. Here we consider
three different min/max feature sets: (1) the 60 features
with an FDR < 0.2 (all microRNAs in Table 2 of [6]), (2)
the 6 features that were most consistently selected dur-
ing cross-validation (bold microRNAs in Table 2 of [6]),
and (3) 16 microRNAs previously reported in the litera-
ture as associated with HCC malignancy. We performed
KMeans clustering on all 89 patients using each of these
feature sets. Note that because the min/max procedure
summarizes expression at the patient-level, clustering
can be performed on patients rather than samples.
While this differs from the biomarker methodology actu-
ally used in the original manuscript, it allows the most
direct comparison to the results reported in this manu-
script. MA-plots of the patient-level min/max expression
profiles show a similar separation between recurrent and
non-recurrent patients as the sample-level analysis
(Additional file 1: Figures S16, S18, and S20). The 60
features seem to show the most separation between the
two clusters; both the 16 and 6 feature sets result in a
few samples that are approximately equidistant from
both clusters.
Next, we examined the Kaplan-Meier recurrence-free
survival curves based on each of the three feature sets
(Additional file 1: Figures S17, S19, S21). All three fea-
ture sets were able to classify patients into good and
poor prognosis groups (p-values < 0.0001). Finally, we
discretized microRNA expression into the four ranges
used for the five microRNA biomarker reported here
and examined the associated between each of the six
microRNAs in feature set 2 and recurrence-free survival
(Additional file 1: Figure S22).
Finally, we fit a Cox proportional hazards model using
each of the three min/max feature sets together with the
Milan criteria to group patients. All three feature sets
were able to distinguish between the Within Milan
group and the Outside Milan & Cluster 1 (poor progno-
sis) group, and there was no discernable difference be-
tween the Within Milan group and the Outside Milan &
Cluster 2 (good prognosis) group (Additional file 1:
Tables S8-S9). However, the estimated hazard ratios
were substantially less using the min/max feature sets.
The 16 and 60 min/max feature sets produced identical
results with hazard ratios of 5.91 with a 95 % confi-
dence interval of (2.87, 12.16). The 6 min/max feature
set resulted in a hazard ratio of 5.29 with a 95 % confi-
dence interval of (2.58, 10.88). In contrast the 5 micro-
RNA biomarker proposed in this manuscript yielded a
hazard ratio of 18.93 with a 95 % confidence interval of
(6.74, 53.14).
Discussion
There are limited donor liver organs available for the
HCC patients in need of liver transplantation. The dis-
covery of biomarkers to predict HCC recurrence after
liver transplantation is therefore important to appropri-
ately use valuable organs. MicroRNAs are popular
markers as they are logistically easy to obtain and can be
effective in classifying tissue types and tumor tissues of
origin [27]. Recent research has shown that a microRNA
biomarker of HCC recurrence when used with the Milan
criteria can improve prediction of recurrence post-
transplantation [6].
HCC patients often present with multiple distinct tumor
foci. The microRNA expression profiles from different
samples in the same patient can differ significantly. This
poses a challenge regarding which microRNA expression
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profiles from the same patient are most strongly associ-
ated with HCC recurrence. We assume that if HCC recurs
after liver transplantation, there is at least one sample, and
corresponding microRNA expression profile, that is re-
sponsible for the recurrence. For patients with multifocal
disease this implies that not all foci are equally responsible
for recurrence. Previous approaches either analyzed only
one sample per patient [9–12] or used summarized
sample-level information from multifocal patients [6],
whereas our approach uses both sample-level and patient-
level information to predict recurrence. This has implica-
tions for patients with highly heterogeneous microRNA
expression profiles.
We identified five microRNAs that appear to be
strongly associated with recurrence post transplantation.
These five microRNAs (miR-122_st, miR-126_st, miR-
15a_st, miR-22_st and miR-30a_st) are down regulated
in samples from recurrent patients. This is consistent
with previous research that reported down-regulation of
miR-30a through comparisons of tumor and non-tumor
tissue and showed reduced disease-free survival times
are significantly associated with down regulation of miR-
30a [25]. Both miR-126 and miR-122 have been previ-
ously reported as down regulated in HCC [11]. Finally,
miR-15a was previously reported to be associated with
shorter recurrence-free survival in HCC patients [9].
These five microRNAs represent a potential biomarker
to predict HCC recurrence after liver transplantation,
when used in concert with the Milan criteria. Develop-
ment and validation of an assay to exclusively measure
these five microRNAs is necessary to determine the clin-
ical utility of the proposed biomarker.
The number of distinct tumor foci is associated with
disease severity as well as recurrence post-transplantation,
and together with tumor size, tumor number is a key
component of the Milan criteria. Furthermore, patients
for whom multiple foci were analyzed are more likely to
exhibit heterogeneous microRNA expression profiles sim-
ply due to a greater number of samples undergoing gen-
omic analysis. For this reason, we do not assign special
significance to the mixed subgroup (Figs. 3 and 4), rather
we consider this subgroup to be comparable to the poor
prognosis subgroup. Patients in either of these subgroups
have at least one poor prognosis sample and have gener-
ally poorer recurrence free survival following transplant-
ation. However, several studies have reported intra-tumor
heterogeneity itself as a predictor of prognosis [28, 29]
and suggested focusing further investigations on the
underlying causes of heterogeneity [30].
A key finding is that for patients with heterogeneous
miRNA expression values, a subset of the within-patient
values can be statistically significant predictors of post
transplant recurrence. In particular, there are 17 patients
from the mixed group who have samples from both
clusters (Additional file 1: Table S2). Patient-level sum-
maries for these patients based on average expression
are potentially misleading due to the heterogeneity be-
tween samples from the same patient. Failure to account
for within-patient heterogeneity can negatively impact
both biomarker development and application. Further-
more, patients with heterogeneous microRNA expres-
sion profiles consistently fall outside the Milan criteria
(Additional file 1: Table S5) and have recurrence free
survival comparable to patients with purely poor prog-
nosis microRNA expression profiles (Fig. 3).
In this work, we have focused on within-patient tumor
heterogeneity. Heterogeneity has also been reported
within individual samples [31, 32] and between patients
with the same cancer subtype [33]. While methods have
been developed to address each of these types of hetero-
geneity [34, 35], careful modeling of these sources of
heterogeneity remains an important challenge in gen-
omic medicine.
Despite these limitations, the results reported in this
manuscript suggest that microRNA expression profiling
of distinct tumor foci could improve prediction of recur-
rence and therefore aid in determining candidates for
transplantation. Specifically, measuring the expression of
these five microRNAs may represent a low cost addition
to standard evaluation. However, increased data collec-
tion comes with a cost – very small tumors with defini-
tive radiographic characteristics of HCC are seen
frequently but difficult to biopsy because of their
small size. Furthermore, small nodules can be difficult
to distinguish from regenerative nodules in the cir-
rhotic liver. Finally, one must weigh the additional in-
formation gained against the risk of multiple biopsies;
in HCC, one is often biopsying a diseased liver with
an increased risk of bleeding. When biopsy is com-
bined with a tumor ablative technique such as radio-
frequency ablation, bleeding risks are minimized by
cauterizing along the biopsy needle tract. Therefore,
tumor sampling for genomic analysis is perhaps best
performed in the Interventional Radiology Suite or
the operating room. The clinical challenge in survey-
ing the entire tumor burden in a patient is formidable
and will require a combination of advances in both
medical and genomic techniques.
Conclusions
In this paper we propose a new approach to combine
sample-level and patient-level information to discover
microRNA biomarkers of HCC recurrence after liver
transplantation. Five specific microRNAs are suggested
as a putative biomarker. It appears that there is a subset
of patients who would benefit from microRNA profiling
when used with the Milan criteria to determine
transplantation.
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